High Point Clinical Trials Center enters a three-year collaboration with ProSciento, a contract research organization (CRO) focused on metabolic diseases, as the center becomes a NASH PASS site partner.
The NASH PASS program from ProSciento matches sites with its proprietary methodology to improve enrollment outcomes in clinical trials for non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
Lorraine Rusch, president of HPCTC, told us that the center – which focuses on Phase I/II clinical proof of concept and translational medicine studies – was interested in the partnership because of the metrics-driven approach ProSciento uses as a means to drive faster recruitment of ”very valuable” patients in a quantitative manner.
Through this partnership, HPCTC will use the NASH PASS protocol to identify individuals eligible for enrollment and contribute to the programs database of prospective clinical study participants evaluated for NAFLD and NASH studies. The center will use a combination of transient elastography (fibroscan), proprietary algorithms, and non-invasive biomarker testing, to determine enrollment eligibility.
In a statement, Rusch added: “These much-needed efforts will spur rapid recruitment of patients into clinical trials which directly translates into novel pharmaceutical products and new methodologies for earlier treatment of this emerging metabolic epidemic.”
